A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT07218341 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Lymphocytic Leukemia
Lymphoma, Small Lymphocytic

Interventions

DRUG: Pirtobrutinib
DRUG: Idelalisib

Sponsor

Eli Lilly and Company